Corporate ActionJul 13, 2026, 06:52 AM
Agenus Secures Up to $340M Private Placement for ROBBIN Trial
AI Summary
Agenus Inc. announced an oversubscribed private placement expected to generate up to $340 million in gross proceeds. The financing includes $85 million upfront and up to $255 million from the exercise of accompanying Series A and Series B purchase warrants. The funds will primarily support the advancement of the registrational ROBBIN Phase 3 clinical trial for its BOT+BAL combination product in neoadjuvant microsatellite-stable (MSS) colon cancer, a market with a potential annual sales opportunity exceeding $7 billion in the US. To focus resources, the company will discontinue financial support for the BATTMAN Phase 3 study.
Key Highlights
- Agenus secured $85 million in upfront gross proceeds from the private placement.
- The private placement could generate up to an additional $255 million upon full exercise of Series A and Series B purchase warrants, totaling $340 million.
- The company agreed to issue 23,035,227 shares of common stock (or pre-funded warrants) at a combined effective purchase price of $3.69 per unit.
- Series A warrants have an exercise price of $4.02 per share, and Series B warrants have an exercise price of $5.03 per share.
- The financing is expected to fund Agenus operations through year-end 2031, assuming full warrant exercise.
- Proceeds will primarily advance the registrational ROBBIN Phase 3 trial for botensilimab and balstilimab (BOT+BAL) in neoadjuvant MSS colon cancer.
- Agenus is discontinuing financial support for the BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer.
- The ROBBIN trial targets a >$7 billion addressable annual sales opportunity in the US.
Price Impact
More from AGEN